Almirall acquires rights to new psoriasis drug in Europe
Almirall has entered a commercialization agreement with Danish MC2 Therapeutics, meaning the Spanish dermatology company will take on European sales of MC2's Wynzora cream for treating psoriasis.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
MC2 Therapeutics has sold off the exclusive rights to selling the firm's new cream treating plaque psoriasis in Europe.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
